REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedReview

Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement.

Sánchez-Quintero María J, Iboleón Andrea, Martín Chaves Laura, Pozo Vilumbrales Bárbara, Carmona-Segovia Ada D M, Martínez López Pilar, Romero-Cuevas Miguel, Rodríguez-Capitán Jorge, Becerra-Muñoz Víctor M, Pavón-Morón Francisco Javier
Biologics : targets & therapy2025DOI: 10.2147/BTT.S504289

Citations

0

Subjects

Non-Human

Study Context

Review papers consolidate the current state of knowledge on a topic. While they don't present new experimental data, they offer valuable context and identify gaps in existing research.

Why This Matters

This research contributes to the growing body of evidence on mots-c. Understanding the mechanisms and clinical applications of these peptides is an active area of investigation.

Citation

Sánchez-Quintero María J, Iboleón Andrea, Martín Chaves Laura et al.. (2025). Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement.. Biologics : targets & therapy. https://doi.org/10.2147/BTT.S504289

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.